Key clinical point: The rates of CIN2+ have declined in younger women since introduction of the HPV vaccine.
Major finding: The rates of vaccine-targeted CIN2+ declined from 52% in 2008 to 30% in 2016 among women aged 18-24 years.
Study details: Analysis of data from the Human Papillomavirus Vaccine Impact Monitoring Program from 2008 to 2016.
Disclosures: One author declared personal fees from Merck during the course of the study. No other conflicts of interest were declared.
McClung N et al. MMWR. 2019 Apr 19;68:337-43.